Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 1
2000 2
2001 1
2002 1
2003 1
2004 3
2008 5
2009 5
2010 5
2011 2
2012 2
2013 2
2014 1
2015 2
2016 3
2017 7
2018 2
2019 1
2020 4
2021 1
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

49 results
Results by year
Filters applied: . Clear all
Page 1
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
Diab A, Tykodi SS, Daniels GA, Maio M, Curti BD, Lewis KD, Jang S, Kalinka E, Puzanov I, Spira AI, Cho DC, Guan S, Puente E, Nguyen T, Hoch U, Currie SL, Lin W, Tagliaferri MA, Zalevsky J, Sznol M, Hurwitz ME. Diab A, et al. Among authors: hoch u. J Clin Oncol. 2021 Sep 10;39(26):2914-2925. doi: 10.1200/JCO.21.00675. Epub 2021 Jul 13. J Clin Oncol. 2021. PMID: 34255535 Clinical Trial.
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy.
Sharma M, Khong H, Fa'ak F, Bentebibel SE, Janssen LME, Chesson BC, Creasy CA, Forget MA, Kahn LMS, Pazdrak B, Karki B, Hailemichael Y, Singh M, Vianden C, Vennam S, Bharadwaj U, Tweardy DJ, Haymaker C, Bernatchez C, Huang S, Rajapakshe K, Coarfa C, Hurwitz ME, Sznol M, Hwu P, Hoch U, Addepalli M, Charych DH, Zalevsky J, Diab A, Overwijk WW. Sharma M, et al. Among authors: hoch u. Nat Commun. 2020 Jan 31;11(1):661. doi: 10.1038/s41467-020-14471-1. Nat Commun. 2020. PMID: 32005826 Free PMC article. Clinical Trial.
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
Diab A, Tannir NM, Bentebibel SE, Hwu P, Papadimitrakopoulou V, Haymaker C, Kluger HM, Gettinger SN, Sznol M, Tykodi SS, Curti BD, Tagliaferri MA, Zalevsky J, Hannah AL, Hoch U, Aung S, Fanton C, Rizwan A, Iacucci E, Liao Y, Bernatchez C, Hurwitz ME, Cho DC. Diab A, et al. Among authors: hoch u. Cancer Discov. 2020 Aug;10(8):1158-1173. doi: 10.1158/2159-8290.CD-19-1510. Epub 2020 May 21. Cancer Discov. 2020. PMID: 32439653 Clinical Trial.
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.
Bentebibel SE, Hurwitz ME, Bernatchez C, Haymaker C, Hudgens CW, Kluger HM, Tetzlaff MT, Tagliaferri MA, Zalevsky J, Hoch U, Fanton C, Aung S, Hwu P, Curti BD, Tannir NM, Sznol M, Diab A. Bentebibel SE, et al. Among authors: hoch u. Cancer Discov. 2019 Jun;9(6):711-721. doi: 10.1158/2159-8290.CD-18-1495. Epub 2019 Apr 15. Cancer Discov. 2019. PMID: 30988166
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.
Charych D, Khalili S, Dixit V, Kirk P, Chang T, Langowski J, Rubas W, Doberstein SK, Eldon M, Hoch U, Zalevsky J. Charych D, et al. Among authors: hoch u. PLoS One. 2017 Jul 5;12(7):e0179431. doi: 10.1371/journal.pone.0179431. eCollection 2017. PLoS One. 2017. PMID: 28678791 Free PMC article.
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.
Charych DH, Hoch U, Langowski JL, Lee SR, Addepalli MK, Kirk PB, Sheng D, Liu X, Sims PW, VanderVeen LA, Ali CF, Chang TK, Konakova M, Pena RL, Kanhere RS, Kirksey YM, Ji C, Wang Y, Huang J, Sweeney TD, Kantak SS, Doberstein SK. Charych DH, et al. Among authors: hoch u. Clin Cancer Res. 2016 Feb 1;22(3):680-90. doi: 10.1158/1078-0432.CCR-15-1631. Clin Cancer Res. 2016. PMID: 26832745
Biotransformations with peroxidases.
Adam W, Lazarus M, Saha-Möller CR, Weichold O, Hoch U, Häring D, Schreier P. Adam W, et al. Among authors: hoch u. Adv Biochem Eng Biotechnol. 1999;63:73-108. doi: 10.1007/3-540-69791-8_4. Adv Biochem Eng Biotechnol. 1999. PMID: 9933982 Review.
2-Aminobenzimidazoles as potent Aurora kinase inhibitors.
Zhong M, Bui M, Shen W, Baskaran S, Allen DA, Elling RA, Flanagan WM, Fung AD, Hanan EJ, Harris SO, Heumann SA, Hoch U, Ivy SN, Jacobs JW, Lam S, Lee H, McDowell RS, Oslob JD, Purkey HE, Romanowski MJ, Silverman JA, Tangonan BT, Taverna P, Yang W, Yoburn JC, Yu CH, Zimmerman KM, O'Brien T, Lew W. Zhong M, et al. Among authors: hoch u. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5158-61. doi: 10.1016/j.bmcl.2009.07.016. Epub 2009 Jul 9. Bioorg Med Chem Lett. 2009. PMID: 19646866
49 results